Skip to main content
SpringerLink
Log in
Book cover

Transplant Infections pp 677–691Cite as

Yeast Infections After Haematopoietic Stem Cell Transplantation

  • Chapter
  • First Online:

  • 1948 Accesses

Abstract

Invasive fungal disease (IFD) caused by yeasts and yeast-like pathogens complicates both autologous and allogeneic haematopoietic stem cell transplantation (HSCT). Epidemiology varies according to geographic location and antifungal prophylaxis and treatment practices. Invasive candidiasis (IC), including bloodstream infection (candidemia) and deep-seated tissue infection, continues to be the most common yeast infection after HSCT. Risk factors, epidemiology, impact of antifungal prophylaxis, diagnostic approaches including non-culture-based tests and emergence of azole and echinocandin resistance in Candida species are discussed. Risks for, timing of onset after HSCT and treatments for IC as well as infections due to rare and endemic yeasts such as Cryptococcus, Rhodotorula, Trichosporon and Coccidiodes are described.

This is a preview of subscription content, log in via an institution.

References

  1. Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J. 2014;44(12b):1315–32.

    CAS  PubMed  Google Scholar 

  2. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007). Cancer. 2009;115(20):4745–52.

    CAS  PubMed  Google Scholar 

  3. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50(1):50–5.

    PubMed  Google Scholar 

  4. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28(5):1071–9.

    CAS  PubMed  Google Scholar 

  5. Ananda-Rajah MR, Cheng A, Morrissey CO, Spelman T, Dooley M, Neville AM, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55(5):1953–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.

    PubMed  Google Scholar 

  7. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.

    CAS  PubMed  Google Scholar 

  8. Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20(1):O50–7.

    CAS  PubMed  Google Scholar 

  9. Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, et al. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61:324–31.

    PubMed  Google Scholar 

  10. Jantunen E, Nihtinen A, Volin L, Juvonen E, Parkkali T, Ruutu T, et al. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. Bone Marrow Transplant. 2004;34(10):891–5.

    CAS  PubMed  Google Scholar 

  11. Chaaban S, Wheat LJ, Assi M. Cryptococcal meningitis post autologous stem cell transplantation. Transpl Infect Dis. 2014;16(3):473–6.

    CAS  PubMed  Google Scholar 

  12. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12):1644–50.

    CAS  PubMed  Google Scholar 

  13. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41(7):975–81.

    PubMed  Google Scholar 

  14. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65(5):1042–51.

    CAS  PubMed  Google Scholar 

  15. Hsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. Clin Microbiol Infect. 2015;21:594.e7–11.

    PubMed  Google Scholar 

  16. Hoenigl M, Strenger V, Buzina W, Valentin T, Koidl C, Wolfler A, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. 2012;67(8):2029–33.

    CAS  PubMed  Google Scholar 

  17. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis. 2002;34(5):591–9.

    PubMed  Google Scholar 

  18. Markowski J, Helbig G, Widziszowska A, Likus W, Kyrcz-Krzemien S, Jarosz U, et al. Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients. Med Sci Monit. 2015;21:1173–80.

    PubMed  PubMed Central  Google Scholar 

  19. Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F, et al. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Ann Hematol. 2014;93(3):493–8.

    CAS  PubMed  Google Scholar 

  20. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309–16.

    CAS  PubMed  Google Scholar 

  21. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine. 2003;82(5):309–21.

    CAS  PubMed  Google Scholar 

  22. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis. 2006;12(10):1508–16.

    PubMed  PubMed Central  Google Scholar 

  24. Trubiano JA, Leung VK, Worth LJ, Teh BW, Thursky KA, Slavin MA. Candida glabrata fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. Leuk Lymphoma. 2015;56:3442–4.

    PubMed  Google Scholar 

  25. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001;28(9):873–8.

    CAS  PubMed  Google Scholar 

  26. Lockhart SR, Wagner D, Iqbal N, Pappas PG, Andes DR, Kauffman CA, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10.

    PubMed  PubMed Central  Google Scholar 

  27. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005;80(6):868–71.

    PubMed  Google Scholar 

  28. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–32.

    PubMed  PubMed Central  Google Scholar 

  29. Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother. 2015;70:2362–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D, et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case–control study in Paris, France. Antimicrob Agents Chemother. 2011;55(11):5358–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case–control studies. Eur J Clin Microbiol Infect Dis. 2006;25(7):419–25.

    CAS  PubMed  Google Scholar 

  32. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8(3), e59373.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36(1):1–53.

    PubMed  Google Scholar 

  34. Rammaert B, Desjardins A, Lortholary O. New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. Mycoses. 2012;55(3):e74–84.

    CAS  PubMed  Google Scholar 

  35. De Castro N, Mazoyer E, Porcher R, Raffoux E, Suarez F, Ribaud P, et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007. Clin Microbiol Infect. 2012;18(6):E185–7.

    PubMed  Google Scholar 

  36. Takemura H, Ohno H, Miura I, Takagi T, Ohyanagi T, Kunishima H, et al. The first reported case of central venous catheter-related fungemia caused by Cryptococcus liquefaciens. J Infect Chemother. 2015;21(5):392–4.

    PubMed  Google Scholar 

  37. Rimek D, Haase G, Luck A, Casper J, Podbielski A. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol. 2004;42(1):481–3.

    PubMed  PubMed Central  Google Scholar 

  38. Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis. 2009;48(11):1566–76.

    PubMed  Google Scholar 

  39. Caira M, Trecarichi EM, Tumbarello M, Leone G, Pagano L. Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Rev Anti Infect Ther. 2011;9(11):1067–75.

    PubMed  Google Scholar 

  40. Fickweiler W, Aries MJ, Enting RH, Vellenga E, De Keyser J. Cryptococcal cerebellitis after chemotherapy and autologous stem cell re-infusion in a patient with multiple myeloma. J Neurol. 2009;256(1):145–6.

    CAS  PubMed  Google Scholar 

  41. Mendpara SD, Ustun C, Kallab AM, Mazzella FM, Bilodeau PA, Jillella AP. Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant. 2002;30(4):259–60.

    CAS  PubMed  Google Scholar 

  42. Kontoyiannis DP, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP, et al. Cryptococcosis in patients with cancer. Clin Infect Dis. 2001;32(11):E145–50.

    CAS  PubMed  Google Scholar 

  43. Miniero R, Nesi F, Vai S, De Intinis G, Papalia F, Targhetta R, et al. Cryptococcal meningitis following a thrombotic microangiopathy in an unrelated donor bone marrow transplant recipient. Pediatr Hematol Oncol. 1997;14(5):469–74.

    CAS  PubMed  Google Scholar 

  44. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect. 2002;17(2):113–20.

    PubMed  Google Scholar 

  45. Nachbaur D, Angelova O, Orth-Holler D, Ditlbacher A, Lackner M, Auberger J, et al. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. Eur J Haematol. 2015;94(3):258–64.

    CAS  PubMed  Google Scholar 

  46. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64(1):68–75.

    PubMed  Google Scholar 

  47. Corzo-Leon DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325–36.

    PubMed  Google Scholar 

  48. Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis. 2009;49(1):e11–7.

    CAS  PubMed  Google Scholar 

  49. Blaes AH, Cavert WP, Morrison VA. Malassezia: is it a pulmonary pathogen in the stem cell transplant population? Transpl Infect Dis. 2009;11(4):313–7.

    CAS  PubMed  Google Scholar 

  50. Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant. 2000;26(6):645–8.

    CAS  PubMed  Google Scholar 

  51. Bufill JA, Lum LG, Caya JG, Chitambar CR, Ritch PS, Anderson T, et al. Pityrosporum folliculitis after bone marrow transplantation. Clinical observations in five patients. Ann Intern Med. 1988;108(4):560–3.

    CAS  PubMed  Google Scholar 

  52. Baker RM, Stegink RJ, Manaloor JJ, Schmitt BH, Stevens JC, Christenson JC. Malassezia pneumonia: a rare complication of parenteral nutrition therapy. JPEN J Parenter Enteral Nutr. 2015.

    Google Scholar 

  53. Alvarez-Perez S, Blanco JL, Pelaez T, Cutuli M, Garcia ME. In vitro amphotericin B susceptibility of Malassezia pachydermatis determined by the CLSI broth microdilution method and Etest using lipid-enriched media. Antimicrob Agents Chemother. 2014;58(7):4203–6.

    PubMed  PubMed Central  Google Scholar 

  54. Camus V, Thibault ML, David M, Gargala G, Compagnon P, Lamoureux F, et al. Invasive Geotrichum clavatum fungal infection in an acute myeloid leukaemia patient: a case report and review. Mycopathologia. 2014;177(5–6):319–24.

    PubMed  Google Scholar 

  55. Picard M, Cassaing S, Letocart P, Verdeil X, Protin C, Chauvin P, et al. Concomitant cases of disseminated Geotrichum clavatum infections in patients with acute myeloid leukemia. Leuk Lymphoma. 2014;55(5):1186–8.

    PubMed  Google Scholar 

  56. Savini V, Catavitello C, Balbinot A, Masciarelli G, Astolfi D, Pompilio A, et al. Multidrug-resistant Geotrichum capitatum from a haematology ward. Mycoses. 2011;54(6):542–3.

    PubMed  Google Scholar 

  57. Henrich TJ, Marty FM, Milner Jr DA, Thorner AR. Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. Transpl Infect Dis. 2009;11(5):458–62.

    CAS  PubMed  Google Scholar 

  58. Choi G, Meijer SL, Hazenberg MD. Disseminated bread yeast fungaemia in a baker’s wife with acute myeloid leukaemia. Br J Haematol. 2012;158(3):298.

    CAS  PubMed  Google Scholar 

  59. Cairoli R, Marenco P, Perego R, de Cataldo F. Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT. Bone Marrow Transplant. 1995;15(5):785–6.

    CAS  PubMed  Google Scholar 

  60. Olver WJ, James SA, Lennard A, Galloway A, Roberts IN, Boswell TC, et al. Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect. 2002;52(4):268–72.

    CAS  PubMed  Google Scholar 

  61. Popiel KY, Wong P, Lee MJ, Langelier M, Sheppard DC, Vinh DC. Invasive Saccharomyces cerevisiae in a liver transplant patient: case report and review of infection in transplant recipients. Transpl Infect Dis. 2015;17(3):435–41.

    CAS  PubMed  Google Scholar 

  62. Papaemmanouil V, Georgogiannis N, Plega M, Lalaki J, Lydakis D, Dimitriou M, et al. Prevalence and susceptibility of Saccharomyces cerevisiae causing vaginitis in Greek women. Anaerobe. 2011;17(6):298–9.

    CAS  PubMed  Google Scholar 

  63. Echeverria-Irigoyen MJ, Eraso E, Cano J, Gomariz M, Guarro J, Quindos G. Saccharomyces cerevisiae vaginitis: microbiology and in vitro antifungal susceptibility. Mycopathologia. 2011;172(3):201–5.

    CAS  PubMed  Google Scholar 

  64. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45(6):1735–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11(2):142–51.

    PubMed  Google Scholar 

  66. Fores R, Ramos A, Orden B, de Laiglesia A, Bautista G, Cabero M, et al. Rhodotorula species fungaemia causes low mortality in haematopoietic stem-cell transplantation. A case report and review. Mycoses. 2012;55(3):e158–62.

    PubMed  Google Scholar 

  67. Mori T, Nakamura Y, Kato J, Sugita K, Murata M, Kamei K, et al. Fungemia due to Rhodotorula mucilaginosa after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2012;14(1):91–4.

    CAS  PubMed  Google Scholar 

  68. Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses. 2011;54(4):318–24.

    CAS  PubMed  Google Scholar 

  69. Girmenia C, Pagano L, Martino B, D’Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43(4):1818–28.

    PubMed  PubMed Central  Google Scholar 

  70. Suzuki K, Nakase K, Kyo T, Kohara T, Sugawara Y, Shibazaki T, et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol. 2010;84(5):441–7.

    PubMed  Google Scholar 

  71. Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis. 2014;16(2):213–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69(11):1403–15.

    CAS  PubMed  Google Scholar 

  73. Mendoza N, Noel P, Blair JE. Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation. Transpl Infect Dis. 2015;17:380–8.

    CAS  PubMed  Google Scholar 

  74. Riley DK, Galgiani JN, O’Donnell MR, Ito JI, Beatty PG, Evans TG. Coccidioidomycosis in bone marrow transplant recipients. Transplantation. 1993;56(6):1531–3.

    CAS  PubMed  Google Scholar 

  75. Glenn TJ, Blair JE, Adams RH. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol. 2005;43(8):705–10.

    PubMed  Google Scholar 

  76. Haydoura S, Wallentine J, Lopansri B, Ford CD, Saad D, Burke JP. Disseminated histoplasmosis in allogeneic bone marrow transplant: a diagnosis not to be missed. Transpl Infect Dis. 2014;16(5):822–6.

    CAS  PubMed  Google Scholar 

  77. Walsh TJ, Catchatourian R, Cohen H. Disseminated histoplasmosis complicating bone marrow transplantation. Am J Clin Pathol. 1983;79(4):509–11.

    CAS  PubMed  Google Scholar 

  78. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002;4(3):148–51.

    CAS  PubMed  Google Scholar 

  79. Jones O, Cleveland KO, Gelfand MS. A case of disseminated histoplasmosis following autologous stem cell transplantation for Hodgkin’s lymphoma: an initial misdiagnosis with a false-positive serum galactomannan assay. Transpl Infect Dis. 2009;11(3):281–3.

    CAS  PubMed  Google Scholar 

  80. Ruiz e Resende LS, Yasuda AG, Mendes RP, Marques SA, Niero-Melo L, Defaveri J, et al. Paracoccidioidomycosis in patients with lymphoma and review of published literature. Mycopathologia. 2015;179(3–4):285–91.

    PubMed  Google Scholar 

  81. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33(1):23–32.

    CAS  PubMed  Google Scholar 

  82. Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92.

    PubMed  Google Scholar 

  83. Cobos-Trigueros N, Morata L, Torres J, Zboromyrska Y, Soriano A, Pitart C, et al. Usefulness of time-to-positivity in aerobic and anaerobic vials to predict the presence of Candida glabrata in patients with candidaemia. J Antimicrob Chemother. 2013;68(12):2839–41.

    CAS  PubMed  Google Scholar 

  84. Fernandez J, Erstad BL, Petty W, Nix DE. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis. 2009;64(4):402–7.

    PubMed  Google Scholar 

  85. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54(5):633–43.

    PubMed  Google Scholar 

  86. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70.

    CAS  PubMed  Google Scholar 

  87. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.

    PubMed  Google Scholar 

  88. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47(6):846–54.

    CAS  PubMed  Google Scholar 

  89. Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57(Pt 3):287–95.

    CAS  PubMed  Google Scholar 

  90. Kami M, Tanaka Y, Kanda Y, Ogawa S, Masumoto T, Ohtomo K, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica. 2000;85(7):745–52.

    CAS  PubMed  Google Scholar 

  91. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 → 3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42(6):2733–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46(12):1864–70.

    CAS  PubMed  Google Scholar 

  93. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39(2):199–205.

    CAS  PubMed  Google Scholar 

  94. Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1 → 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46(3):1009–13.

    PubMed  Google Scholar 

  95. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878–85.

    CAS  PubMed  Google Scholar 

  96. Abe M, Kimura M, Araoka H, Taniguchi S, Yoneyama A. Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia. Med Mycol. 2014;52(8):835–40.

    CAS  PubMed  Google Scholar 

  97. Naselli A, Faraci M, Lanino E, Morreale G, Cangemi G, Bandettini R, et al. Persistence of high-level (1,3)-beta-D-glucan after candidemia following autologous peripheral SCT in a pediatric patient. Bone Marrow Transplant. 2015;50(1):137–8.

    CAS  PubMed  Google Scholar 

  98. Mikulska M, Furfaro E, Del Bono V, Gualandi F, Van Lint MT, Miletich F, et al. Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients. Clin Vaccine Immunol. 2011;18(3):518–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Duffner U, Abdel-Mageed A, Dahl K, Fogg G, Hester J. Serum (1 → 3)-beta-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. Bone Marrow Transplant. 2012;47(1):151–2.

    CAS  PubMed  Google Scholar 

  100. Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y. False-positive plasma (1 → 3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol. 2004;80(1):97–8.

    PubMed  Google Scholar 

  101. Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013;5(182):182ra54.

    Google Scholar 

  102. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9.

    CAS  PubMed  Google Scholar 

  103. Lau A, Halliday C, Chen SC, Playford EG, Stanley K, Sorrell TC. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol. 2010;48(3):811–6.

    PubMed  Google Scholar 

  104. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49(2):665–70.

    PubMed  PubMed Central  Google Scholar 

  105. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54(9):1240–8.

    CAS  PubMed  Google Scholar 

  106. Jaye DL, Waites KB, Parker B, Bragg SL, Moser SA. Comparison of two rapid latex agglutination tests for detection of cryptococcal capsular polysaccharide. Am J Clin Pathol. 1998;109(5):634–41.

    CAS  PubMed  Google Scholar 

  107. Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994;32(7):1680–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2), e21.

    PubMed  PubMed Central  Google Scholar 

  109. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7(3):375–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Jongwutiwes U, Sungkanuparph S, Kiertiburanakul S. Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients. Jpn J Infect Dis. 2008;61(2):111–5.

    PubMed  Google Scholar 

  111. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690–9.

    CAS  PubMed  Google Scholar 

  112. Melcher GP, Reed KD, Rinaldi MG, Lee JW, Pizzo PA, Walsh TJ. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol. 1991;29(1):192–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  113. Suwantarat N, Dalton JB, Lee R, Green R, Memon W, Carroll KC, et al. Large-scale clinical validation of a lateral flow immunoassay for detection of cryptococcal antigen in serum and cerebrospinal fluid specimens. Diagn Microbiol Infect Dis. 2015;82(1):54–6.

    CAS  PubMed  Google Scholar 

  114. Huang HR, Fan LC, Rajbanshi B, Xu JF. Evaluation of a new cryptococcal antigen lateral flow immunoassay in serum, cerebrospinal fluid and urine for the diagnosis of cryptococcosis: a meta-analysis and systematic review. PLoS One. 2015;10(5), e0127117.

    PubMed  PubMed Central  Google Scholar 

  115. Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2014;58(1):113–6.

    CAS  PubMed  Google Scholar 

  116. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321–5.

    PubMed  PubMed Central  Google Scholar 

  117. Rivet-Danon D, Guitard J, Grenouillet F, Gay F, Ait-Ammar N, Angoulvant A, et al. Rapid diagnosis of cryptococcosis using an antigen detection immunochromatographic test. J Infect. 2015;70(5):499–503.

    PubMed  Google Scholar 

  118. Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54.

    PubMed  Google Scholar 

  119. McMullan BJ, Halliday C, Sorrell TC, Judd D, Sleiman S, Marriott D, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One. 2012;7(11), e49541.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Bader O, Weig M, Taverne-Ghadwal L, Lugert R, Gross U, Kuhns M. Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect. 2011;17(9):1359–65.

    CAS  PubMed  Google Scholar 

  121. Haigh J, Degun A, Eydmann M, Millar M, Wilks M. Improved performance of bacterium and yeast identification by a commercial matrix-assisted laser desorption ionization-time of flight mass spectrometry system in the clinical microbiology laboratory. J Clin Microbiol. 2011;49(9):3441.

    PubMed  PubMed Central  Google Scholar 

  122. Saracli MA, Fothergill AW, Sutton DA, Wiederhold NP. Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Med Mycol. 2015;53:736–42.

    CAS  PubMed  Google Scholar 

  123. Vella A, De Carolis E, Vaccaro L, Posteraro P, Perlin DS, Kostrzewa M, et al. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol. 2013;51(9):2964–9.

    PubMed  PubMed Central  Google Scholar 

  124. Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A, Jillwin TJ, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. Clin Microbiol Infect. 2015;21(4):372–8.

    CAS  PubMed  Google Scholar 

  125. Lacroix C, Gicquel A, Sendid B, Meyer J, Accoceberry I, Francois N, et al. Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clin Microbiol Infect. 2014;20(2):153–8.

    CAS  PubMed  Google Scholar 

  126. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532–8.

    CAS  PubMed  Google Scholar 

  127. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother. 2010;54(12):5042–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Ruggero MA, Topal JE. Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy. Transpl Infect Dis. 2014;16(3):469–72.

    CAS  PubMed  Google Scholar 

  129. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 2014;20(11):1833–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50(4):1199–203.

    CAS  PubMed  PubMed Central  Google Scholar 

  131. Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, et al. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. J Antimicrob Chemother. 2013;68(4):922–6.

    CAS  PubMed  Google Scholar 

  132. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56(11):5898–906.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.

    CAS  PubMed  Google Scholar 

  134. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.

    CAS  PubMed  Google Scholar 

  135. Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009;53(12):5026–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, Marks DI, et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15:128.

    PubMed  PubMed Central  Google Scholar 

  137. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52(9):3022–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  138. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  139. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–6.

    PubMed  Google Scholar 

  140. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451–6.

    CAS  PubMed  Google Scholar 

  141. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  142. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  143. Lerolle N, Raffoux E, Socie G, Touratier S, Sauvageon H, Porcher R, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20(11):O952–9.

    CAS  PubMed  Google Scholar 

  144. Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(4):507–15.

    CAS  PubMed  Google Scholar 

  145. Langebrake C, Rohde H, Lellek H, Wolschke C, Kroger NM. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice. Clin Transplant. 2014;28(3):286–91.

    CAS  PubMed  Google Scholar 

  146. Kabbara N, Lacroix C, Peffault de Latour R, Socie G, Ghannoum M, Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica. 2008;93(4):639–40.

    Google Scholar 

  147. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.

    CAS  PubMed  Google Scholar 

  148. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60(3):613–8.

    CAS  PubMed  Google Scholar 

  149. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54(1):184–90.

    CAS  PubMed  Google Scholar 

  150. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2013;68(1):206–13.

    Google Scholar 

  151. Bassetti M, Merelli M, Ansaldi F, de Florentiis D, Sartor A, Scarparo C, et al. Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS One. 2015;10(5), e0127534.

    PubMed  PubMed Central  Google Scholar 

  152. Liu CY, Huang LJ, Wang WS, Chen TL, Yen CC, Yang MH, et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect. 2009;58(2):154–60.

    CAS  PubMed  Google Scholar 

  153. Khalid A, Clough LA, Symons RC, Mahnken JD, Dong L, Eid AJ. Incidence and clinical predictors of ocular candidiasis in patients with Candida fungemia. Interdiscip Perspect Infect Dis. 2014;2014:650235.

    PubMed  PubMed Central  Google Scholar 

  154. Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53(3):262–8.

    PubMed  Google Scholar 

  155. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med. 1989;149(10):2226–8.

    CAS  PubMed  Google Scholar 

  156. Fernandez-Cruz A, Cruz Menarguez M, Munoz P, Pedromingo M, Pelaez T, Solis J, et al. The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. Eur J Clin Microbiol Infect Dis. 2015;34:1543–9.

    CAS  PubMed  Google Scholar 

  157. Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18(4):E99–109.

    CAS  PubMed  Google Scholar 

  158. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis—a contraindication to marrow transplantation? Blood. 1994;84(8):2811–4.

    CAS  PubMed  Google Scholar 

  159. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion. 1994;34(3):226–32.

    CAS  PubMed  Google Scholar 

  160. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case–control analysis of 491 episodes of Candida species bloodstream infections. Cancer. 2004;101(12):2859–65.

    PubMed  Google Scholar 

  161. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322.

    PubMed  Google Scholar 

  162. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20 Suppl 3:76–98.

    CAS  PubMed  Google Scholar 

  163. Cahuayme-Zuniga L, Kontoyiannis DP. Is it safe to proceed with stem cell transplant in cancer patients treated for cryptococcal infection? A focus on recent IDSA cryptococcal guidelines. Clin Infect Dis. 2010;50(12):1687–9.

    PubMed  Google Scholar 

  164. Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, et al. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis. 2013;57(4):543–51.

    CAS  PubMed  Google Scholar 

  165. Perfect JR. The impact of the host on fungal infections. Am J Med. 2012;125(1 Suppl):S39–51.

    CAS  PubMed  Google Scholar 

  166. Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol. 2008;25(3):135–40.

    PubMed  Google Scholar 

  167. Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Guillen H, Burgaleta C. Rhodotorula mucilaginosa catheter-related fungaemia in a patient with multiple myeloma. Mycoses. 2011;54(4):e214–6.

    CAS  PubMed  Google Scholar 

  168. Hofmeyr A, Slavin MA. Emerging opportunistic yeast infections in haematology patients. Leuk Lymphoma. 2006;47(9):1736–7.

    PubMed  Google Scholar 

  169. Schoepfer C, Carla H, Bezou MJ, Cambon M, Girault D, Demeocq F, et al. Malassezia furfur septicemia after bone marrow graft. Arch Pediatr. 1995;2(3):245–8.

    CAS  PubMed  Google Scholar 

  170. de St Maurice A, Frangoul H, Coogan A, Williams JV. Prolonged fever and splenic lesions caused by Malassezia restricta in an immunocompromised patient. Pediatr Transplant. 2014;18(8):E283–6.

    PubMed  PubMed Central  Google Scholar 

  171. Viscomi SG, Mortele KJ, Cantisani V, Glickman J, Silverman SG. Fatal, complete splenic infarction and hepatic infection due to disseminated Trichosporon beigelii infection: CT findings. Abdom Imaging. 2004;29(2):228–30.

    CAS  PubMed  Google Scholar 

  172. Alegre A, Algora M, Penalver MA, Llanos ML, Perez-Pons C, Garcia Plaza I, et al. Focal hepato-splenic mycosis caused by Trichosporon beigelii in a patient with acute leukemia. Sangre. 1991;36(4):311–4.

    CAS  PubMed  Google Scholar 

  173. Chen CY, Chen YC, Tang JL, Yao M, Huang SY, Tsai W, et al. Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol. 2003;82(2):93–7.

    PubMed  Google Scholar 

  174. von Eiff M, Essink M, Roos N, Hiddemann W, Buchner T, van de Loo J. Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies. Blut. 1990;60(4):242–8.

    Google Scholar 

  175. Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002;71(4):260–7.

    CAS  PubMed  Google Scholar 

  176. Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann Med. 2005;37(4):259–69.

    PubMed  Google Scholar 

  177. Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia. 2008;166(3):121–32.

    PubMed  Google Scholar 

  178. Kontoyiannis DP, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis. 2004;36(8):564–9.

    PubMed  Google Scholar 

  179. Thompson 3rd GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009;64(1):79–83.

    CAS  PubMed  Google Scholar 

  180. Ikuta K, Torimoto Y, Yamamoto M, Okamura N, Hosoki T, Sato K, et al. Successful treatment of systemic Geotrichum capitatum infection by liposomal amphotericin-B, itraconazole, and voriconazole in a Japanese man. Intern Med. 2010;49(22):2499–503.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Peter MacCallum Cancer Centre, 2 St. Andrews Place, East Melbourne, Melbourne, VIC, 3002, Australia

    Jason A. Trubiano M.B.B.S. (Hons.), F.R.A.C.P. & Monica A. Slavin M.B., B.S., M.D.

  2. Department of Microbiology and Infectious Diseases, Westmead Hospital, Corner of Darcy and Hawkesbury Road, Westmead, Sydney, NSW, 2145, Australia

    Sharon C.-A. Chen Ph.D., M.B.B.S.

Authors
  1. Jason A. Trubiano M.B.B.S. (Hons.), F.R.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharon C.-A. Chen Ph.D., M.B.B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monica A. Slavin M.B., B.S., M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monica A. Slavin M.B., B.S., M.D. .

Editor information

Editors and Affiliations

  1. Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    Per Ljungman

  2. Tufts University School of Medicine Tufts Medical Center, Boston, MA, USA

    David Snydman

  3. University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Michael Boeckh

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Trubiano, J.A., Chen, S.CA., Slavin, M.A. (2016). Yeast Infections After Haematopoietic Stem Cell Transplantation. In: Ljungman, P., Snydman, D., Boeckh, M. (eds) Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-319-28797-3_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28797-3_37

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28795-9

  • Online ISBN: 978-3-319-28797-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation